Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 37.31
(-0.8%)
USD 37.31
(-0.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.05 Billion USD | 264.22% |
| 2022 | -642 Million USD | 32.7% |
| 2021 | -954 Million USD | 16.54% |
| 2020 | -1.14 Billion USD | 36.15% |
| 2019 | -1.79 Billion USD | -18.09% |
| 2018 | -1.51 Billion USD | -209.61% |
| 2017 | -489.6 Million USD | -197.47% |
| 2016 | -164.58 Million USD | 56.87% |
| 2015 | -381.6 Million USD | -8.0% |
| 2014 | -353.33 Million USD | 30.23% |
| 2013 | -506.42 Million USD | -119.75% |
| 2012 | -230.45 Million USD | -250.27% |
| 2011 | 153.36 Million USD | 81.81% |
| 2010 | 84.35 Million USD | 189.95% |
| 2009 | -93.77 Million USD | -116.0% |
| 2008 | -43.41 Million USD | -237.89% |
| 2007 | 31.48 Million USD | 21.93% |
| 2006 | 25.82 Million USD | -82.08% |
| 2005 | 144.1 Million USD | -34.47% |
| 2004 | 219.9 Million USD | 11.77% |
| 2003 | 196.75 Million USD | 55.13% |
| 2002 | 126.83 Million USD | 1385.88% |
| 2001 | 8.53 Million USD | -87.31% |
| 2000 | 67.24 Million USD | 20.3% |
| 1999 | 55.9 Million USD | 4.1% |
| 1998 | 53.7 Million USD | 159.42% |
| 1997 | 20.7 Million USD | 288.18% |
| 1996 | -11 Million USD | 70.11% |
| 1995 | -36.8 Million USD | -2966.67% |
| 1994 | -1.2 Million USD | 94.0% |
| 1993 | -20 Million USD | -440.54% |
| 1992 | -3.7 Million USD | 75.66% |
| 1991 | -15.2 Million USD | -2433.33% |
| 1990 | -600 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.68 Billion USD | 3.88% |
| 2024 Q1 | 1.62 Billion USD | 53.68% |
| 2023 Q2 | 1.04 Billion USD | -0.26% |
| 2023 FY | 1.05 Billion USD | 264.22% |
| 2023 Q3 | 1.05 Billion USD | 0.26% |
| 2023 Q4 | 1.05 Billion USD | 0.22% |
| 2023 Q1 | 1.05 Billion USD | 263.86% |
| 2022 Q2 | 701.39 Million USD | 3.19% |
| 2022 FY | -642 Million USD | 32.7% |
| 2022 Q1 | 679.7 Million USD | 171.25% |
| 2022 Q4 | -642 Million USD | -170.6% |
| 2022 Q3 | 909.4 Million USD | 29.66% |
| 2021 FY | -954 Million USD | 16.54% |
| 2021 Q1 | 495.63 Million USD | 143.36% |
| 2021 Q4 | -954 Million USD | -246.98% |
| 2021 Q2 | 715.39 Million USD | 44.34% |
| 2021 Q3 | 649.04 Million USD | -9.27% |
| 2020 Q4 | -1.14 Billion USD | -789.09% |
| 2020 Q1 | 293.39 Million USD | 116.39% |
| 2020 FY | -1.14 Billion USD | 36.15% |
| 2020 Q2 | 259 Million USD | -11.72% |
| 2020 Q3 | 165.87 Million USD | -35.96% |
| 2019 Q2 | -1.67 Billion USD | -740.62% |
| 2019 Q3 | 408.31 Million USD | 124.38% |
| 2019 Q4 | -1.79 Billion USD | -538.39% |
| 2019 FY | -1.79 Billion USD | -18.09% |
| 2019 Q1 | 261.46 Million USD | 117.25% |
| 2018 Q3 | 139.11 Million USD | 171.21% |
| 2018 Q4 | -1.51 Billion USD | -1189.62% |
| 2018 FY | -1.51 Billion USD | -209.61% |
| 2018 Q1 | -493.66 Million USD | -0.83% |
| 2018 Q2 | -195.35 Million USD | 60.43% |
| 2017 Q2 | -339.17 Million USD | -172.69% |
| 2017 Q3 | 425.31 Million USD | 225.4% |
| 2017 Q4 | -489.6 Million USD | -215.12% |
| 2017 FY | -489.6 Million USD | -197.47% |
| 2017 Q1 | 466.58 Million USD | 383.49% |
| 2016 Q4 | -164.58 Million USD | -141.56% |
| 2016 FY | -164.58 Million USD | 56.87% |
| 2016 Q1 | -308.34 Million USD | 19.2% |
| 2016 Q2 | 361.42 Million USD | 217.21% |
| 2016 Q3 | 396.05 Million USD | 9.58% |
| 2015 Q3 | 337.38 Million USD | 191.53% |
| 2015 Q4 | -381.6 Million USD | -213.11% |
| 2015 Q1 | 304.35 Million USD | 186.14% |
| 2015 FY | -381.6 Million USD | -8.0% |
| 2015 Q2 | -368.61 Million USD | -221.11% |
| 2014 Q3 | 153.83 Million USD | 17.32% |
| 2014 Q2 | 131.12 Million USD | 112.79% |
| 2014 Q1 | 61.62 Million USD | 112.17% |
| 2014 FY | -353.33 Million USD | 30.23% |
| 2014 Q4 | -353.33 Million USD | -329.69% |
| 2013 Q4 | -506.42 Million USD | -1283.45% |
| 2013 Q2 | -78.53 Million USD | -172.3% |
| 2013 Q1 | 108.61 Million USD | 147.13% |
| 2013 FY | -506.42 Million USD | -119.75% |
| 2013 Q3 | -36.6 Million USD | 53.39% |
| 2012 Q1 | 163.9 Million USD | 6.88% |
| 2012 Q3 | 141.89 Million USD | -2.41% |
| 2012 Q4 | -230.45 Million USD | -262.41% |
| 2012 Q2 | 145.4 Million USD | -11.29% |
| 2012 FY | -230.45 Million USD | -250.27% |
| 2011 Q1 | 68.99 Million USD | -18.21% |
| 2011 FY | 153.36 Million USD | 81.81% |
| 2011 Q3 | 157.59 Million USD | 35.58% |
| 2011 Q2 | 116.23 Million USD | 68.48% |
| 2011 Q4 | 153.36 Million USD | -2.69% |
| 2010 Q3 | 45.21 Million USD | -56.37% |
| 2010 Q2 | 103.61 Million USD | 140.87% |
| 2010 Q1 | 43.01 Million USD | 148.06% |
| 2010 FY | 84.35 Million USD | 189.95% |
| 2010 Q4 | 84.35 Million USD | 86.58% |
| 2009 Q3 | -136.76 Million USD | -69.5% |
| 2009 Q1 | -120.09 Million USD | -176.63% |
| 2009 FY | -93.77 Million USD | -116.0% |
| 2009 Q2 | -80.68 Million USD | 32.82% |
| 2009 Q4 | -89.5 Million USD | 34.55% |
| 2008 Q3 | -96.7 Million USD | 64.72% |
| 2008 Q4 | -43.41 Million USD | 55.11% |
| 2008 FY | -43.41 Million USD | -237.89% |
| 2008 Q1 | -103.57 Million USD | -428.95% |
| 2008 Q2 | -274.13 Million USD | -164.68% |
| 2007 FY | 31.48 Million USD | 21.93% |
| 2007 Q1 | 73.27 Million USD | 183.76% |
| 2007 Q2 | 41.06 Million USD | -43.96% |
| 2007 Q3 | 69.78 Million USD | 69.94% |
| 2007 Q4 | 31.48 Million USD | -54.88% |
| 2006 FY | 25.82 Million USD | -82.08% |
| 2006 Q1 | 144.09 Million USD | -0.0% |
| 2006 Q2 | 38.55 Million USD | -73.24% |
| 2006 Q3 | 38.18 Million USD | -0.97% |
| 2006 Q4 | 25.82 Million USD | -32.37% |
| 2005 Q4 | 144.1 Million USD | 48.65% |
| 2005 Q3 | 96.93 Million USD | -60.52% |
| 2005 Q2 | 245.55 Million USD | 1.88% |
| 2005 Q1 | 241.02 Million USD | 9.6% |
| 2005 FY | 144.1 Million USD | -34.47% |
| 2004 Q4 | 219.9 Million USD | 0.9% |
| 2004 FY | 219.9 Million USD | 11.77% |
| 2004 Q3 | 217.95 Million USD | 6.88% |
| 2004 Q2 | 203.92 Million USD | 7.24% |
| 2004 Q1 | 190.15 Million USD | -3.35% |
| 2003 Q2 | 125.23 Million USD | -21.46% |
| 2003 Q3 | 176.38 Million USD | 40.84% |
| 2003 FY | 196.75 Million USD | 55.13% |
| 2003 Q1 | 159.46 Million USD | 25.72% |
| 2003 Q4 | 196.75 Million USD | 11.55% |
| 2002 Q2 | 91.38 Million USD | 79.11% |
| 2002 Q1 | 51.01 Million USD | 497.69% |
| 2002 FY | 126.83 Million USD | 1385.88% |
| 2002 Q4 | 126.83 Million USD | 31.81% |
| 2002 Q3 | 96.22 Million USD | 5.3% |
| 2001 Q1 | 100.79 Million USD | 49.89% |
| 2001 Q4 | 8.53 Million USD | -93.85% |
| 2001 Q3 | 138.83 Million USD | 20.0% |
| 2001 Q2 | 115.69 Million USD | 14.78% |
| 2001 FY | 8.53 Million USD | -87.31% |
| 2000 Q3 | 40.83 Million USD | 12.86% |
| 2000 FY | 67.24 Million USD | 20.3% |
| 2000 Q2 | 36.18 Million USD | 19.3% |
| 2000 Q1 | 30.33 Million USD | -45.74% |
| 2000 Q4 | 67.24 Million USD | 64.67% |
| 1999 Q1 | 62.2 Million USD | 15.83% |
| 1999 Q4 | 55.9 Million USD | 8.54% |
| 1999 FY | 55.9 Million USD | 4.1% |
| 1999 Q3 | 51.5 Million USD | 0.0% |
| 1999 Q2 | 51.5 Million USD | -17.2% |
| 1998 FY | 53.7 Million USD | 159.42% |
| 1998 Q4 | 53.7 Million USD | 40.94% |
| 1998 Q3 | 38.1 Million USD | 8.24% |
| 1998 Q2 | 35.2 Million USD | 13.18% |
| 1998 Q1 | 31.1 Million USD | 50.24% |
| 1997 Q3 | 6.7 Million USD | 937.5% |
| 1997 FY | 20.7 Million USD | 288.18% |
| 1997 Q1 | -400 Thousand USD | 96.36% |
| 1997 Q4 | 20.7 Million USD | 208.96% |
| 1997 Q2 | -800 Thousand USD | -100.0% |
| 1996 FY | -11 Million USD | 70.11% |
| 1996 Q4 | -11 Million USD | 29.94% |
| 1996 Q1 | -12.2 Million USD | 66.85% |
| 1996 Q2 | -15.6 Million USD | -27.87% |
| 1996 Q3 | -15.7 Million USD | -0.64% |
| 1995 Q3 | -14.9 Million USD | -77.38% |
| 1995 Q1 | -5.6 Million USD | -366.67% |
| 1995 Q4 | -36.8 Million USD | -146.98% |
| 1995 FY | -36.8 Million USD | -2966.67% |
| 1995 Q2 | -8.4 Million USD | -50.0% |
| 1994 FY | -1.2 Million USD | 94.0% |
| 1994 Q1 | -20.3 Million USD | -1.5% |
| 1994 Q3 | -4 Million USD | 36.51% |
| 1994 Q4 | -1.2 Million USD | 70.0% |
| 1994 Q2 | -6.3 Million USD | 68.97% |
| 1993 FY | -20 Million USD | -440.54% |
| 1993 Q1 | -18.1 Million USD | -389.19% |
| 1993 Q2 | -12 Million USD | 33.7% |
| 1993 Q3 | -6.8 Million USD | 43.33% |
| 1993 Q4 | -20 Million USD | -194.12% |
| 1992 FY | -3.7 Million USD | 75.66% |
| 1992 Q4 | -3.7 Million USD | -164.29% |
| 1992 Q1 | -5.3 Million USD | 65.13% |
| 1992 Q2 | -1 Million USD | 81.13% |
| 1992 Q3 | -1.4 Million USD | -40.0% |
| 1991 Q1 | -14.2 Million USD | -2266.67% |
| 1991 Q4 | -15.2 Million USD | -31.03% |
| 1991 FY | -15.2 Million USD | -2433.33% |
| 1991 Q3 | -11.6 Million USD | 57.82% |
| 1991 Q2 | -27.5 Million USD | -93.66% |
| 1990 Q4 | -600 Thousand USD | 0.0% |
| 1990 FY | -600 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 1310.194% |
| Dynavax Technologies Corporation | 106.63 Million USD | -888.674% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 3244.549% |
| Perrigo Company plc | 3.32 Billion USD | 68.265% |
| Illumina, Inc. | 1.21 Billion USD | 13.157% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 96.072% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 1025.71% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 87.198% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 91.799% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -626.704% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 3990.306% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -14569.167% |
| Waters Corporation | 1.96 Billion USD | 46.223% |
| Biogen Inc. | 6.28 Billion USD | 83.234% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 14948.915% |
| Evolus, Inc. | 63.7 Million USD | -1554.852% |
| Adicet Bio, Inc. | -142 Million USD | 842.404% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 11793.356% |
| bluebird bio, Inc. | 108.57 Million USD | -871.045% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -129.84% |
| FibroGen, Inc. | 56.76 Million USD | -1757.193% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 7.924% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -15030.045% |
| Homology Medicines, Inc. | 18.43 Million USD | -5618.246% |
| Geron Corporation | 14.76 Million USD | -7042.287% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 33.498% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -432.286% |
| Myriad Genetics, Inc. | 88.1 Million USD | -1096.678% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 2043.145% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1046.368% |
| Zoetis Inc. | 4.76 Billion USD | 77.861% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 10568.404% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 49.748% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -178.357% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 111.023% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 7334.923% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -3206.486% |
| Verastem, Inc. | -37.27 Million USD | 2928.137% |
| Nektar Therapeutics | 210.24 Million USD | -401.462% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 627.609% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 2964.561% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -8.87% |
| OPKO Health, Inc. | 230.68 Million USD | -357.022% |
| Exelixis, Inc. | -73.05 Million USD | 1543.221% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -494.627% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 878.636% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 798.083% |
| uniQure N.V. | -102.95 Million USD | 1124.053% |
| Imunon, Inc. | -4.69 Million USD | 22534.811% |
| Blueprint Medicines Corporation | 702.83 Million USD | -50.003% |
| Insmed Incorporated | 721.62 Million USD | -46.098% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 23.652% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 3477.24% |
| TG Therapeutics, Inc. | 17.86 Million USD | -5802.323% |
| Incyte Corporation | -3.17 Billion USD | 133.205% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -37.669% |